{
    "nctId": "NCT00228358",
    "briefTitle": "Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine",
    "officialTitle": "A Phase I Study of Infusion of HER-2/Neu Specific T Cells in Patients With Advanced Stage HER-2/Neu Expressing Cancers Who Have Received a HER-2/Neu Vaccine",
    "overallStatus": "COMPLETED",
    "conditions": "HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 8,
    "primaryOutcomeMeasure": "Feasibility of expanding HER2 specific T cells ex vivo to achieve a target T cell expansion of 1x10^10 HER2 specific T cells",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with progressive HER2/neu overexpressing metastatic breast, ovarian, or non-small cell lung cancer not considered curable by conventional therapies, including trastuzumab\n\n  * Extra-skeletal disease that can be accurately measured \\>= 10 mm by standard imaging techniques that can include but not limited to computed tomography (CT), positron emission tomography (PET), magnetic resonance imaging (MRI)\n  * Skeletal or bone-only disease which is measurable by Fludeoxyglucose F 18 (FDG) PET imaging will also be allowed\n  * Patients with ovarian cancer may have measurable disease; however, their only indication of progression may be an abnormal CA-125\n* Patients must have documented HER-2/neu overexpression in their tumor (either primary or metastasis) as was required per the eligibility criteria of their original vaccination protocol\n* Patients must have received HER2-specific vaccinations while enrolled on a HER2 vaccine protocol approved at the University of Washington Human Subjects Division\n* Patients must have undergone leukapheresis after vaccination through a protocol approved at the University of Washington Human Subjects Division and have product stored for clinical use\n* Subjects must have a Performance Status Score (Zubrod/Eastern Cooperative Oncology Group \\[ECOG\\] Scale) = 0 or 1\n* Patients can be currently receiving trastuzumab and/or lapatinib and/or hormonal therapy and/or bisphosphonate therapy\n\n  * Patients on trastuzumab and/or lapatinib must have adequate cardiac function as demonstrated by multi gated acquisition (MUGA) scan or echocardiogram (ECHO) within 90 days of eligibility determination\n* Patients must be off all immunosuppressive treatments, and/or systemic steroid therapy, for at least 14 days prior to initiation of study treatment\n* Patients must be off chemotherapy and trastuzumab for at least 1 week prior to the first infusion of T cells\n* Men and women of reproductive ability must agree to contraceptive use during the study and for one month after the final T cell infusion\n* Patients with a history of brain metastases must have a stable head imaging study within 30 days of enrollment\n* White blood cells (WBC) \\>= 3000/mm\\^3\n* Absolute neutrophil count (ANC) \\>= 1000/mm\\^3\n* Hemoglobin (Hgb) \\>= 10 mg/dl\n* Platelets \\>= 75,000mm\\^3\n* Serum creatinine =\\< 2.0 mg/dl or creatinine clearance \\> 60 ml/min\n* Total bilirubin =\\< 2.5 mg/dl\n* Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =\\< 3 times ULN\n\nExclusion Criteria:\n\n* Concurrent enrollment in other treatment studies\n* Patients with any of the following cardiac conditions:\n\n  * Symptomatic restrictive cardiomyopathy\n  * Unstable angina within the last 4 months prior to enrollment\n  * New York Heart Association functional class III-IV heart failure on active treatment\n* Patients with any clinically significant autoimmune disease uncontrolled with treatment\n* Pregnant or breast-feeding women\n* Known history of hypersensitivity to diphtheria toxin or interleukin (IL)-2 (only for subjects enrolled in Group B)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}